

## Index

### a

- $\alpha$  interaction domain 71
- $\alpha_1$  subunit 69 ff.
- $\alpha_2$ - $\delta$  subunit 57, 69 ff.
- $\alpha$ -Dendrotoxin (DTX) 217
  - selectivity 219
- A-278637 344 ff.
- A-411873 323
- acetylcholine receptor deficiency 408
- AChR 410
- action potential 44, 55
- adipocytes 244 ff.
  - brown fat 244
  - glucose transporter 244
  - white fat 244
- afterhyperpolarization 314
- Ageneopsis aperta* 131
- alkaloid 319, 328
- ALMOND modul 432 ff.
- Alzheimer's disease 317
- ambasilide 278
- amiloride-sensitive epithelial sodium channel 397
- 4-aminopyridine 222
- amiodarone 29, 278
- amitriptyline,  $\text{Na}_v$  blocking activity 186
- amlodipine 89 ff.
- amygdala-kindling model 357 ff., 361
- anandamide 91
- ancillary calcium channel subunits 69 ff., 77
- Andersen-Tawil syndrome 383
- anesthetics 87
- anosmia 251
- antiarrhythmic drugs 9, 278
- anticonvulsant
  - amygdala-kindling 357 ff.
  - 6 Hz model 361
  - maximal electroshock 357 ff.
  - pentylenetetrazol 357 ff.
  - picrotoxin 357
- antiepileptic drugs, receptor sites 9
- antiepileptics 87
- anxiety 369
  - canopy test 369 ff.
- apamin 242, 244, 326 f.
- apoptosis 237
  - Fas receptor 237
  - mitochondria 237
- aryloxindole 321
- arylpyrrole 323
- asthma 324
- ATP-sensitive potassium channel  $\text{K}_{\text{ATP}}$  335, 385
- atrial effective refractory period (AERP) 291
- atrial fibrillation 276
- atrial vulnerability 291
- autism 396
- autoantibodies 238
- autoimmune diseases 247 ff.
- autosomal dominant
  - juvenile myoclonic epilepsy 412
  - nocturnal frontal lobe epilepsy 410
- auxiliary subunit in
  - $\text{K}_v\beta$  11
  - $\text{KChIp1-4}$  11
  - $\text{minK}$  11
- auxiliary subunits
  - $\text{Ca}_v\alpha_2$  10
  - $\text{Ca}_v\beta$  10
  - $\text{Ca}_v\delta$  10
  - $\text{Ca}_v\gamma$  10
  - $\text{Na}_v\beta_1$  9
  - of  $\text{K}^+$  channels 198
- AVE0118 287, 289
- azaindole 323
- azimilide 278

**b**

- β cell rest 341
- β subunits 69
- β-cell overwork 341
- β-tryptase inhibitors 440
- β1-integrin 236
- B cell 215, 234, 237, 247
  - memory B cell 237 ff.
  - proliferation 237
  - T<sub>CM</sub> 247 ff.
  - T<sub>EM</sub> 247 ff.
- Ba<sup>2+</sup> 86
- Ball, channel expression 238
- barnidipine 89 ff.
- Bartter syndrome 406
  - type 2 383
  - type 4 407
- barttin 406
- Becker's syndrome 403
- benidipine 89 ff.
- benign familial neonatal
  - convulsions 388
  - infantile seizures 396
- benzamides 235
  - binding site 227
  - Hill coefficient 227
  - PAC 227
  - SAR 227
  - selectivity 227
  - trans-N-propyl-carbamoyloxy PAC 227
- benzimidazolinone 326, 329
- benzimidazolone 320
- benzoxazolone 326, 329
- benzothiazepine class 103
- bepidil 278
- binding 56
- biophysical properties 159
  - activation 160
  - recovery from inactivation 160
  - state-dependent sodium channel blocker 161
  - steady-state inactivation 160
  - use-dependent 162
- bladder 245
  - hyperactivity 315
  - K<sup>+</sup> channel expression 245
  - overactivity 323, 326
- blockers
  - aliphatic monoamines 138 ff.
  - ω-agatoxin-IIIa 128
  - conclusions 140 ff.
  - ω-conotoxin-GVIA 127
  - ω-conotoxin MVIIC 128
  - dialkyl-dipeptidylamines 132
  - dihydropyridines 139 ff.
  - ethanol 140 ff.
  - huwentoxin-I 127
  - imidazolines 139 ff.
  - non-specific N 128
  - piperazines 136 ff.
  - small organic molecule 132 ff.
  - substituted L-amino acids 132
  - substituted piperidines 136 ff.
  - unsaturated hydrocarbons 138 ff.
  - venom of the spiders 128
  - volatile anaesthetics 139
- BMS 191011 322
- BMS-180448 338
- BMS-189269 320
- BMS-191095 338
- BMS-204352 312, 321
- Boltzmann curve 23
- Boltzmann function 26
- bone resorption 250
- borderline SMEI 395
- Brugada syndrome 394 f.
- bupivacaine 29, 171
  - structure 172

**c**

- CACNA1A 401 f.
- CACNA1C 400
- CACNA1F 401
- CACNA1H 403
- CACNA1S 399
- CACNB4 402
- calcium activators 100
- calcium channel 9, 65, 382, 399
  - L-type 27
  - N-type 122
  - T-type 23, 27, 42, 84
- calcium channel blockers 100
  - abscisic acid 108
  - amlodipine 102
  - benzacocine CGP 108
  - benzothiazepine 103
  - BMY 20064 104
  - calciseptine 115
  - calcludine 115
  - clotrimazole 114
  - 1,4-dihydropyridine 103
  - diltiazem 101 ff.
  - dodecanol 114
  - dodecylamine 114
  - felodipine 102
  - FPL 64176 108

- gene delivery 118
- HOE 166 104
- isradipine 102
- L 652,469 104
- L-calchin 115
- MCI 176 104
- McN-5691 104
- McN-6186 104
- MDL 12,330 104
- menthol 104, 114
- mibefradil 115
- nicaldipine 102
- nifedipine 101, 103
- nimodipine 102
- peptide toxins 115
- phenylalkylamine 103
- praziquantel 117
- (-) S bay k 8644 108
- (+) S 202-791 108
- SR 33557 104
- structure-activity relationships 102
- tetrandine 104
- tinuvin 770 114
- verapamil 101, 103
- vitamin D 115
- WAY 141520 117
- calcium channel knockout 76
- calcium currents
  - L-type 10, 65, 101
  - N-type 10, 65, 123
  - P/Q-type 10, 65
  - R-type 10, 65
  - T-type 10, 65, 84
- calcium ions 65
- calcium signaling 235
- calcium-activated K<sup>+</sup> channel 196, 199 ff., 310
- calcium-dependent inactivation 70
- candidate gene approach 381
- canopy test 369
- carbamazepine 21, 32
  - derivatives 173
  - metabolism 173
  - neuropathic pain 173
  - structure 173
- carrageenan model 359
- Cav1.1 399
- Cav1.2 400
  - L-type 31
- Cav1.4 401
- Cav2.1 401
- Cav2.2 32, 403
- CC2-DMPE 52
- CCR7 233 f., 250
  - T<sub>EM</sub> 247
- CD4<sup>+</sup> 233
- CD8<sup>+</sup> 233
- CD27 234, 237
- CD45RA 233 f.
  - T<sub>EM</sub> 247
- CDP-840 434, 436
- central memory (T<sub>CM</sub>) 232
- cerebellar ataxia 314
- cetiedil 324
- CFTR chloride channel 407
- CGS-7181 323
- CGS-7184 323
- chalcone-16 230
  - pharmacological properties 225
  - selectivity 220
- channelopathy 381 ff., 412
- charybdotoxin (ChTX) 57, 216 f., 318
  - selectivity 219
  - sequence 218
- childhood absence epilepsy 396
- chloride channel 382, 403
- chloroquine 430
- chlorzoxazone 326
- CHO cells 429
- chromanol 293B 278
- chronic constriction injury model 357
- chronic graft versus host disease (GvHD)
  - 215, 237, 247
  - pathogenesis 250
  - therapies 250
- ChTX 233, 235, 242, 245 f.
- cisapride 430, 434
- Cl<sub>Ca</sub> 50
- ClC-1 403
- ClC-2 404
- ClC-5 405
- ClC-7 406 f.
- ClC-Ka and ClC-Kb channels 406 f.
- CLCN-K 406
- CLCN1 403
- CLCN2 404
- CLCN5 405
- CLCN7 406
- Clofilium 278
- ClogP 431
- clotrimazole 242, 319, 324
- CMR 431
- CNG Channels 390 f.
- CoMFA 434
- CoMSiA 434
- cone snail toxins
  - disulfide pattern 221

- four disulfide bonds 221
- congenital myasthenic syndromes 408
- congenital stationary night blindness
  - type 2 401
- Conus catus* 127
- Conus geographus* 130
- Conus magus* 130
  - $\omega$ -conotoxin-MVIIA 126
- conus striatus* 130
- $\omega$ -conotoxin GVIA 66, 126 f.
- $\omega$ -conotoxin MVIIA 68
- CoroNa Green 58
- correolide 215, 217, 224, 235, 245
  - C18-analog 227
  - binding-site 226
  - pharmacological properties 225
  - selectivity 220, 227
  - *spachea correa* 226
  - structure 223
  - T cell proliferation 227
- CP-339818 224 f.
  - selectivity 220, 225
  - structure 223
- CRAC 234, 236
- crobenetine
  - analgesic properties 177
  - regiochemistry 176
  - structure 177
  - treatment of ischemic stroke 177
- cromakalim
  - bladder inhibitory effects 344
  - cardioprotective effects 338
  - clinical effects on bladder 343
  - in vitro (pig bladder strip) 347
  - pharmacological tools 335
- cyclic nucleotide-gated channel 390
- CYP2C9 inhibition 440
- cystic fibrosis 316, 407
  
- d**
- DC-EBIO 326
- de novo* design 299
- dehydrosoyasaponin-1 324
- delayed type hypersensitivity (DTH) 236
- deltamethrin 55
- dendrotoxin 57
- Dent's disease 405
- DHS-1 324
- Di-ANEPPS 51, 55
- diabetes 340
- dialkyl-dipeptidylamines 132 ff.
- diazoxide
  - antihypertensive 336
  - cardioprotective effects 338
  - $\beta$  cell function 341
  - hypoglycemia 336
  - insulinomas 340
  - nesidioblastosis 340
  - pharmacological tools 335
  - polycystic ovary syndrome 340
  - side effects 341
- DiBAC 51 f.
- dichlorophenylpyrazolopyrimidines 228
- diclofenac 375 ff.
- dihydropyridine 21, 325
- 1,4-dihydropyrimidine 109
- 1,4-dihydropyridine class 103
  - activators 113
  - amlodipine 106, 108
  - benidipine 106
  - clinically available 110
  - clinidipine 106
  - conformational requirements 109
  - felodipine 106
  - isradipine 106
  - lacidipine 106
  - lercanidipine 106
  - manidipine 106
  - nicardipine 106
  - nifedipine 106
  - nilvadipine 106
  - nimodipine 106
  - nisoldipine 106
  - nitrendipine 106
  - NO-releasing activities 113
  - privileged structure 106, 114
  - QSAR 109
  - state-dependence 110
  - state-dependent interactions 111 f.
  - stereoselectivity 107
  - structure–activity relationships 107, 110
  - vascular cardiac selectivity 111
- dihydropyridine  $K_{ATP}$  blocker 345
- dihydropyridine  $K_{ATP}$  openers 345
- dihydropyridines 66, 89, 139
- dihydroquinolones
  - CP-339818 224
  - $^{125}$ I-ChTX-displacement 224
  - mechanism of channel block 224
  - patch-clamp 224
  - $^{86}$ Rb-efflux 224
  - WIN-17317-3 224
- diisopyramide 28
- diltiazem 21, 223, 278
- diphenylurea 320
- disease association 162

- channelopathies 162
  - febrile seizures plus (GEFS+) type 2 163
  - GEFS+ type I 163
  - hyperkalemic periodic paralysis 162
  - long Q-T syndrome type 3 163
  - myotonias 162
  - paramyotonia congenita 163
  - potassium aggravated myotonia 163
  - primary erythralgia 163
  - disease indications 246 ff.
  - distribution of VGCCs 66
  - dofetilide 57
  - dopamine 328
  - drain plug model 434
  - dronedarone 278
  - drug acquired LQTS 447
  - drug binding sites 207
  - d-sotalol 278
  - ducky mouse 77
- e**
- EAE 247
  - 1-EBIO 317, 326, 329
  - effector memory ( $T_{EM}$ ) 232
  - efonidipine 89 ff.
  - electrical signals 7
  - ENaC 397
  - ENaC channel 397
  - encainide 28
  - epilepsy 77, 355 ff.
  - epilepsy with grand mal seizures
    - on awakening 404
  - episodic ataxia 76
    - type 1 386
    - type 2 401
  - epithelia 245
    - $K^+$  channel expression 245
  - epitope spreading 252
  - erectile dysfunction 322
  - erg-2 242
  - erythromycin 57
  - ethanol 140
  - ethosuximide 87 ff.
  - 1-ethyl-2-benzimidazolinone 317
- f**
- familial hemiplegic migraine 401
  - Fas receptor 237
    - apoptosis 237
  - fast channel syndrome 410
  - febrile seizures associated with
    - afebrile seizures 396
  - felodipine 89
  - Filistata hibernalis* 128, 131
  - flecainide 28, 278
  - FLIPR 58
  - FLIPR<sup>®</sup> 33
  - flunarizine 88 ff.
  - fluorescence 56 f.
  - fluorescence resonance energy transfer 429
  - flupirtine (Katadolon<sup>®</sup>) 355 ff.
  - formalin model 359 ff.
  - frequency dependence 45
  - FRET 52 f., 55
- g**
- $G\beta\gamma$  74
  - GABA<sub>A</sub> 412
    - receptors 412
  - gabapentin 57
  - gain of function 382 ff., 385, 388, 390 f.,
    - 393 ff., 403, 410
  - gate 22
  - gating 208
    - state 19
  - gene 214
  - generalized febrile epilepsy plus 395, 397
  - genetic and acquired channelopathies 381
  - GIRK 50
  - GLRA 410
  - GLRB 410
  - glucose transporter 244
  - glyburide
    - anti-arrhythmic activity 339
    - antidiabetic agent 336
    - insulin-releasing properties 340
    - pharmacological tools 335
  - glycine receptors 410
  - goats model of AF 291
  - Grammostola spatulata* 128, 130
  - Grave's disease 238
  - green fluorescent protein 53
  - GRIND-based model 432
  - [<sup>14</sup>C]-guanidium, ion flux 58
  - $\gamma$  subunits 69
- h**
- haloperidol 88 ff.
  - Hashimoto's thyroiditis 238
  - HCN Channels 391
  - hearing 314
  - heart 246
    - $K^+$  channel expression 246
  - HEK cells 429
  - hERG 38, 55, 57, 59, 242, 389 f.
    - channel 207, 428

- channel mutations 430
  - h-erg potassium channel 389, 444 ff.
  - antihistamines terfenadine 449, 454
  - antipsychotic drugs 450
  - arsenic trioxide 454
  - astemizole 449
  - blockers, not LQT 454
  - cisapride 450
  - clarythromycin 453
  - clomiphene 454
  - erythromycin 453
  - fluoroquinolone antibacterials 450
  - grepafloxacin 450
  - haloperidol 450
  - interactions 449
  - macrolide antibiotics 453
  - sparfloxacin 450
  - thioridazine 450
  - trafficking effects 454
  - verapamil 454
  - high-throughput screening 33
  - high voltage activated (HVA) currents 66
  - hinge 14
  - HIV-related neuropathy 243
  - HMR-1556 278
  - HMR1883 340
  - Hodgkin–Huxley 20
    - model 30
  - homology model 300
  - homopiperidine 324
  - HQSAR, hologram QSAR 431
  - hyperkplexia 411
  - hyperinsulinaemic hypoglycaemia
    - of infancy 385
  - hyperinsulinemia 340 f.
  - hyperkalaemic periodic paralysis 76, 393, 399
  - hyperpolarization-activated cyclic
    - nucleotide gated channels 391
  - hypomagnesaemia with secondary
    - hypocalcaemia 392
  - hypoxia 237
  - 6 Hz “psychomotor” test 361
- i**
- $I_{Kr}$  389
  - iberiotoxin 319
  - ICA-17043 324
  - ICH 444 ff.
    - E14 446
    - guidelines 445 ff.
    - S7A 446 ff.
    - S7B 446
  - Ig-fold 9
  - IgD 234, 237
  - $IK_{ACh}$  50
  - $IK_R$  42
  - $IK_S$  42
  - $IK_{ur}$  276
  - IL2 production 225
  - imidazolines 139
  - immunological synapse 235 ff.
  - imodipine 89
  - inactivation 22
  - incontinence 323
  - indications 186
  - indole urea 323
  - infantile malignant osteopetrosis 406
  - infantile spasms 395
  - inflammatory pain 359
  - inherited disorders 381 ff.
  - insomnia 412
  - integrated risk assessment 444 ff., 455 ff.
  - intermediate-conductance 310
  - intractable childhood epilepsy 395
  - inward rectifiers 200 ff., 383
  - inward-rectifying  $K^+$  channels 12, 196
  - ion flux 57 f.
  - ischemia 320
  - ischemic preconditioning 337
  - IsK 386
  - isoflurane 87 ff.
  - isolated cardiac conduction defect 394 f.
  - isridapine 89
- j**
- Jervell and Lange-Nielson syndrome 387
  - juvenile absence epilepsy 404
  - juvenile myoclonic epilepsy 402, 404
- k**
- $K_{ATP}$  drug-related patent applications 349
  - $K_{ATP}$  openers for alopecia 348
  - $K_{ATP}$  partial agonist 346
  - $K_{ATP}$  radioligand 345
  - kaliotoxin 215 ff., 246, 250
    - selectivity 219
    - sequence 218
  - Katadolon® 355
  - $K_{Ca}1.1$  312, 318
  - $K_{Ca}2.1$  327
  - $K_{Ca}2.2$  327
  - $K_{Ca}2.3$  327
  - $K_{Ca}3.1$  231, 238, 245 f., 315, 324
    - expression 233 ff., 234
  - $K_v\beta 2$  235
  - $K^+$  channel 11, 382, 385

- auxiliary subunits 201
  - blockers 214
  - classification 194
  - crystal structure 201
  - diseases 194
  - herg 29
  - toxins 210
  - KCMA3 312
  - KCNA1 386
  - KCNE1 386f.
  - KCNE2 389
  - KCNH2 389
  - KCNJ1 383
  - KCNJ2 383
  - KCNJ11 385
  - KCNMA1 312
  - KCNMB1 314
  - KCNN1 316
  - KCNN2 316
  - KCNN3 316
  - KCNN4 315
  - KCNQ channels 355 ff.
  - KCNQ1 386 f.
  - KCNQ2 388
  - KCNQ3 388
  - KCNQ4 388
  - KCNT2 312
  - KcsA channel 428, 430
  - KDR kinase inhibitors 437
  - khellinones 223
    - chalcone-16 223, 227, 230
    - Hill coefficients 230
    - dimers 230
    - selectivity 230
  - kinetics 45
  - Kir1.1 383
  - Kir2.1 241, 243, 383
  - Kir3 50
  - Kir4.1 243
  - Kir6.2 385
  - KirBac1.1 channel 428
  - Kv1.1 232, 385 f.
  - Kv1.2 232
  - Kv1.3
    - apoptosis 237
    - B-lymphocytes 214
    - expression 233 ff.
    - gene 214
    - hypoxia 237
    - knockout mice 251
    - $K_v\beta 2$  235
    - macrophage 214
    - microglia 214
    - null mice 215
    - olfactory bulb 214
    - oligodendrocytes 214
    - osteoclasts 214
    - peptide inhibitors 216
    - phosphorylation 235
    - physiological role 231 ff.
    - platelets 214
    - single-channel conductance 231
  - Kv1.4 243
  - Kv1.5 240, 242 f.
    - channel blocker 275
    - homology modul 275
    - pharmacophore model 275
  - Kv1.6 232, 243
  - Kv3.1 232
    - null mice 232
  - Kv7.2–7.5 355
  - Kv11.1 242
  - Kv11.2 242
  - Kvap channel 428
  - KvLQT1 386, 388
  - KYS05044 91 ff.
- I**
- Lambert-Eaton myasthenic syndrome 402
  - lamotrigine 32, 175 ff.
    - binding site 170 ff.
    - history 168
    - indications 168
    - pharmacology 171 ff.
    - sodium channel block 171 ff.
    - structure 170 ff.
  - large-conductance 310
  - laudanosine 328
  - lead identification 296
    - pharmacophore-based 299
    - structure-based 299
  - lethargic mouse 77
  - levosimendan 339, 349
  - Liddle's syndrome 397
  - lidocaine 27 ff., 31, 175 ff., 181 ff.
    - binding site 171 f.
    - history 168
    - indications 168
    - mechanism of block 169 ff.
    - neuropathic pain 168, 172 ff.
    - postherpetic neuralgia 172 ff.
    - structure 172
  - ligand binding 204
  - ligand operated channels 382
  - ligand-based
    - chemometric models 430

- model 428
  - ligand-gated channels 408
  - local anesthetics, receptor sites 9
  - long QT syndrome (LQTS) 389 f., 444
    - type 1 386
  - loss of function 382 ff., 383, 386 ff., 394 ff., 401, 403, 405 f.
  - low voltage activated (LVA) currents 65
  - L-type 66
  - L-type calcium channel 42, 399
    - blockers 89
    - calcium activators 100
    - calcium antagonists 100
    - calcium channel blockers 100
    - calcium entry blockers 100
    - gabapentin 116
    - pregabalin 116
    - splice variants 112
    - state-dependent interactions 112
    - $\alpha_1\text{-}\beta$  subunit site of interaction 117
    - $\alpha_2\delta$  subunit 116
  - L-type channel 100, 122
    - cinnarizine 101
    - flunarizine 101
    - prenylamine 100
    - verapamil 100
  - LQT7 384
  - lymphocytes 55
- m**
- macrophage 239 ff.
    - KCa1.1 240
    - K<sup>+</sup> channel 239
    - Kir2.1 241
    - Kv1.3 239
    - Kv1.5 240
    - membrane potential 240
    - [<sup>3</sup>H]thymidine incorporation 240
  - malignant hyperthermia 399
  - margatoxin 215 ff., 219, 232, 235, 237, 240, 245
    - pharmacological properties 225
    - selectivity 219
    - sequence 218
  - marketed K<sub>ATP</sub> modulating drugs 336
  - maxikdiol 324
  - maximal electroshock 357
  - MaxiPost™ 321, 362 ff.
  - M currents 355, 388
  - mechanisms of drug block 169
    - use-dependent 170
  - meclufenamic acid 375 ff.
  - membrane potential sensing dyes 51 ff.
    - memory T cells
      - central memory (T<sub>CM</sub>) 232
      - effector memory (T<sub>EM</sub>) 232
    - methsuximide 87 ff.
    - 5-methoxypsoralen 229
    - mexiletine 171, 175 ff.
      - analogues 180 ff.
      - structure 172
    - mexilitine 21, 29
    - mibefradil 21, 24 f., 90 ff.
    - mice lacking the Kv1.3 232
    - microglia 241 ff.
      - amoeboid 241 ff.
      - K<sup>+</sup> channel 241 ff.
      - migration 242
      - proliferation 242
      - ramified 241 ff.
      - respiratory burst 242
    - migraine 364 ff.
    - MinK 386 f.
    - minoxidil 338, 348
    - MiRP1 38, 389 f.
    - mitochondrial K<sub>ATP</sub> (mito-K<sub>ATP</sub>) channel 335, 337
      - opener 338
    - MK-499 430, 434
    - 5-MOP, Structure 223
    - modulated receptor hypothesis 46
    - modulated receptor model 24, 27
    - monophasic action potentials (MAP) 291
    - MS 232, 237 f., 247
    - Mthk channel 428, 430
    - multiple sclerosis (MS) 215
      - EAE 247
      - MS lesion 247
      - myelin antigen-specific T cells 247
      - therapies 248
    - muscle acetylcholine receptors (AChR) 408
    - mutations 381 ff.
    - myasthenic syndrome 393 f.
    - myocardial ischemia 337
    - myogenic bladder overactivity 343
    - myotonia congenita 403
- n**
- Na<sub>v</sub> subtypes 169
  - Na<sub>v</sub> blockers 187
    - indications 186
    - neurodegenerative disease states 186
    - new structural classes 180
  - Na<sup>+</sup>-K<sup>+</sup>-ATPase 245
  - natural killer cells 239
  - Nav1.1 395



- Nav1.2 396
  - Nav1.4 393
  - Nav1.5 394
  - neurogenic bladder overactivity 343
  - neuroleptics 88
  - neurological disorders 329
  - neuromuscular transmission 403
  - neuronal AChR 410
  - neuropathic pain 355 ff.
  - neuropeptide Y, Y5-receptor antagonists 436
  - neuroprotection 322, 326
  - NFAT 236
  - Ni<sup>2+</sup> 86
  - nifedipine 27, 89, 325
    - structure 223
  - night blindness 76
  - nimodipine 89
  - NIP-141 284
  - NIP-142 284
  - nitrendipine 27, 89, 223, 325
  - nitrous oxide 88
  - NMDA receptor 27
  - NN414 341 f.
  - NNC 55-0118 341
  - NO-releasing activities,
    - 1,4-dihydropyridines 113
  - nociception 32, 320
  - non-selective cation channels 382, 390
  - novel K<sub>ATP</sub> chemotypes 347
  - NS-4 320, 322
  - NS-8 323
  - NS-309 326, 328
  - NS-1608 320
  - NS-1619 320
  - NS-4591 328
  - NS-1619 314
  - N-type 66
  - N-type calcium channel
    - blockers 123 ff.
    - pharmacology 123
  - N-type channel peptide antagonists
    - ω-agatoxin IVA 131
    - ω-conotoxins 130
    - DW13.3 131
    - huwentoxin-I 131
    - *in vitro* 130
    - *in vivo* 130
    - kurtoxin 131
    - ω-phonetoxin IIA 131
    - SNX-325 131
  - N-type channels 403
    - Cav2.2 122 f.
    - ω-conotoxin-GVIA 126
    - GABA<sub>B</sub> 123
    - inorganic cations 124
    - peptide blockers 125
    - specific blockers 125
- O**
- obesity 251
  - octanol 87
  - Ohm's law 39
  - olfactory bulb 244
    - super-smeller 244
  - oligodendrocytes 243 ff.
    - differentiation 243
    - K<sup>+</sup> expression 243
    - precursors 243
    - proliferation 243
  - oocytes 429
  - Ornithoctonus huwena* 131
    - huwentoxin-I 127
  - OSK1 219
  - osteoclasts 245 ff.
    - bone resorption 246
    - K<sup>+</sup> channel expression 245 ff.
    - membrane potential 246
  - overactive bladder (OAB) 343
  - oxadiazolone 322
- P**
- PAC 224
    - Hill coefficient 227
    - pharmacological properties 225
    - selectivity 220, 227
    - structure 223
    - trans-N-propyl-carbamoyloxy PAC 227
  - pain 32, 76
  - pain (inflammatory),
    - carrageenan assay 358 ff.
  - pain (neuropathic)
    - chronic constriction injury (CCI) 357 ff.
    - spared nerve assay 359 ff.
    - spinal nerve ligation 359 ff.
    - streptozotocin assay 369 ff.
  - pain (persistent), formalin assay 358 ff.
  - pancreatic β-cell K<sub>ATP</sub> 335
  - PAP-1 217
    - oral availability 229
    - pharmacological properties 225
    - selectivity 220, 229
    - structure 223
  - Parabuthus transvaalicus* 131
  - Paramyotonia congenita* 393
  - patch clamp 39 ff., 59

- assay 429
  - paxilline 240, 319
  - Pb<sup>2+</sup> 86
  - PBFI 58
  - PDE4 inhibitors 434
  - penfluridol 88 ff.
  - pentyletetrazol 357 ff.
  - peptide inhibitors 216 ff.
  - peptide toxins 318, 327
  - peptidomimetic 228
  - Per-Arnt-Sim domain 428
  - pharmacophore model 299
    - 3-dimensional 431
  - phenobarbital 87 ff.
  - phenyl-stilbene A 228
    - structure 223
  - phenylalkylamine class 105
  - phenytoin 20, 27, 32, 87 ff., 175 ff.
    - history 168
    - indications 168
    - neurodegenerative disease states 186
    - neuroprotection 174 ff.
    - structure 174 ff.
  - phoneutria nigriventer* 131
    - venom of the spiders 128
  - phylogenetic analysis 154 ff.
    - evolutionary perspective 156 ff.
    - four-domain family 154 ff.
    - Na channel genes 156 ff.
    - SCN1A 157 ff.
    - SCN2A 157 ff.
    - SCN3A 157 ff.
    - SCN4A 157 ff.
    - SCN5A 157 ff.
    - SCN8A 157 ff.
    - SCN9A 157 ff.
    - SCN10A 157 ff.
    - SCN12A 157 ff.
  - physicochemical models, 2-dimensional 431
  - pig model of AF 291
  - pinacidil 335 f., 341, 347
    - cardioprotective effects 338
  - pimozide 88 ff.
  - piperidines
    - binding site 226
    - Hill coefficient 226
    - patch clamp 226
    - <sup>86</sup>Rb-efflux 226
    - selectivity 226
    - UK-78282 226
  - pK<sub>a</sub> 431
  - PKA kinase anchoring proteins 73
  - planar patch clamp 48 ff.
  - platelets 246
    - K<sup>+</sup> channel expression 246
  - polymerase chain reaction 381
  - pore 9-10, 12 f.
  - Posicor™ 90
  - positional cloning 381
  - potassium channels; *see* K<sup>+</sup> channel 11, 382, 385
  - potassium selectivity region 428
  - potassium-aggravated myotonia 393
  - P/Q-type 66
  - pregabalin 57
  - Prialt® (ziconotide) 32
  - primary and tertiary structure 152
    - IFM motif 154
    - membrane topology 152
    - P-loop 152
  - privileged structures 103, 296
  - progesterone 230
  - propafenone 278
  - propofol 87 ff.
  - prostate cancer 326
  - protein crystal structure 59
  - protein kinase C 73
  - protein superfamily 7
  - provisional safety margins,
    - 30-fold margin 456
  - pseudohypoaldosteronism type 1 397
  - psora-4 217, 224, 235
    - Hill coefficient 229
    - PAP-1 229
    - pharmacological properties 225
    - selectivity 220, 229
    - structure 223
  - psoralens 224
    - H37 229
    - 5-methoxypsoralen 229
    - PAP-1 229
    - pharmacophore 229
    - psora-4 229
    - ruta graveolens 229
    - SARs 229
  - psoriasis 215, 247
    - autoantigens 249
    - pathogenesis 249
    - therapies 250
  - purkinje fiber 59
- q**
- QT interval 384 f., 387 f., 390, 394 f.
  - QT-prolongion 434
  - quantitative structure activity relationship (QSAR) 431

- quinidine 28, 278  
quinine 223  
quinolinium 328  
quinolinone 322
- r**
- RA 247  
ralfinamide 177 ff.  
– pain models 178 ff.  
– pharmacokinetics 178 ff.  
– SAR (structure–activity relationship) 178 ff.  
– structure 177  
– treatment of neuropathic pain 177 ff.  
<sup>86</sup>Rb, ion flux 58  
reduced repolarization reserve 457  
remodeled atria 291  
rescaffolding 298  
restenosis 316  
retigabine 355 ff.  
retina 245  
– K<sup>+</sup> channel expression 245  
retinitis pigmentosa 390  
rheumatoid arthritis (RA) 215, 237  
– pathogenesis 249  
– synovial fluid 249  
right bundle branch block 395  
riluzole 326, 329  
R-type 66  
rubidium efflux assay 428 f.  
*Ruta graveolens* 229  
ryanodine receptor 399
- s**
- S20951 289  
safety pharmacology 444  
safinamide  
– epilepsy 177 ff.  
– Parkinson's disease 177 ff.  
– restless legs syndrome 177 ff.  
– structure 177  
SAR 137 f.  
sarcolemmal cardiac K<sub>ATP</sub> 335  
– blocker 339  
SBFI 58  
SCN1A 395  
SCN2A 396  
SCN4A 393  
SCN5A 394 f.  
SCNB1 397  
scorpion toxins  
– contacts with channel 216  
– disulfids pattern 216  
– sequence 218  
– structure 216  
screen sequence 38  
SCREENIT 457  
sea anemone toxins 221  
– disulfide pattern 221  
– functional dyad 221  
– sequence 218, 221  
– structure 221  
seal resistance 48  
*Segestria florentina* 128, 131  
selective 2<sup>nd</sup> generation K<sub>ATP</sub> modulating drugs 349 f.  
selectivity  
– hERG channel 301  
– Kv1.5 301  
sertindole 440  
severe myoclonic epilepsy of infancy 395  
ShK 215, 248  
– pharmacological properties 225  
– selectivity 220, 222  
– ShK-Dap 220, 222, 235  
– ShK-F6CA 220, 222  
– structure 221  
ShK(L5) 217, 220, 222, 225, 235 f., 246  
– plasma level 248  
– selectivity 222  
– toxicity 248  
sickle cell anemia 324  
similarity searches 298  
sinus node dysfunction 391  
site-directed mutagenesis 50, 302  
Sjögren's syndrome 238  
SK<sub>Ca</sub> 327  
Slo 312  
slow channel syndrome 409  
small molecules inhibitors 222  
small-conductance 310  
smooth muscle K<sub>ATP</sub> 335  
snake toxins  
– α-dendrotoxin 220  
– disulfide pattern 220  
SNX-482 68  
sodium channel expression 157  
– central nervous system 157  
– peripheral nervous system 157  
– subcellular expression 158  
sodium channels 7, 28, 31, 151, 382, 397  
spinal nerve ligation (SNL)  
(Chung) model 361 ff.  
spinocerebellar ataxia 76  
– type 6 401  
S4 regions 30 f.

- S4 segment 30
- SS9947 289
- SSR149744C 278
- stargazer 77
- state-dependent 56, 112
  - block 44, 112
  - inhibition 20, 112
- states 37 ff., 46 ff., 53, 112
  - closed 37, 44 ff., 55, 112
  - inactivated 37, 44, 46, 55, 112
  - open 37, 44 f., 55, 112
- steroids 230
- Stichodactyla helianthus* toxin (ShK)
  - ShK(L5) 217
  - ShK-Dap<sup>22</sup> 217
  - ShK-F6CA 217
- streptozotocin model 369
- stroke 243, 322
- structure-based model 428
- subdural hematoma 325
- substituted L-amino acids 132 ff.
- sulfimidebenzamidoindanes 228
- sulfonylurea-receptor 208, 385
- super-smeller 244
- SUR1/Kir6.2 openers 340
- SUR2B splice variants 344
- SUR2B/Kir6.2 openers 343
- surface plasmon resonance 429
- synprint 75
- syntaxin 1 75
- systemic lupus erythematosus 238
  
- t**
- tactile allodynia 359 ff.
- tail current 44
- T cell 215, 231 ff.
  - <sup>3</sup>H-thymidine incorporation 225
  - activation 234
  - calcium signaling 235
  - human 231 ff.
  - IL2 production 225
  - membrane potential 235
  - memory 232, 250
  - minipig 231 ff.
  - mouse 231 ff.
  - naïve 231 ff., 250
  - proliferation 225, 233
  - rat 231 ff.
  - T<sub>CM</sub> 236 ff.
  - T<sub>EM</sub> 236 ff.
- tlymphocyte 231 ff.
- T<sub>CM</sub> 236 ff., 247 ff.
- T1DM 247
  
- T<sub>EM</sub> 236 ff., 247, 247 ff.
- terfenadine 430, 434
- tetraethylammonium 207, 222
- tetraphenylporphyrins 228
  - structure 223
- tetrodotoxin (TTX) 42, 168
  - *in vivo* evaluation 178 ff.
  - structure 178 ff.
- TH-1177 91 ff.
- thermal hyperalgesia 359
- Thomsen's disease 403
- thorough QT/QTc study 448
- three-dimensional QSAR 434
- torsade de pointes 449
- toxins 86
- TRAM-34 232, 236, 240, 248, 315
- TRAM-39 324
- transient receptor potential channels 392
- transmural dispersion of repolarization 458
- transplant rejection
  - pathogenesis 250
  - therapies 250
- triphenylmethyl 324
- triterpene 324
- TRPM6 392
- TTX
  - analgesia 180 ff.
  - binding site 169 ff.
  - blocking properties 169 ff.
  - *in vivo* efficacy 179 ff.
  - neurodegenerative disease states 186
  - selectivity 169 ff.
- two-electrode voltage clamp 50
- two-pore K<sup>+</sup> channels 197, 200 ff.
- <sup>3</sup>H-thymidine incorporation 225
- T-type 66
- T-type Ca<sup>2+</sup> channels 42, 84
  - CACNA1G 84
  - CACNA1H 84
  - CACNA1I 84
  - Cav 3.1 (or  $\alpha 1G$ ) 84
  - Cav 3.3 ( $\alpha 1I$ ) 84
  - characteristics 85
  - hypertension 92
  - kidney function 93
  - knockout mice 93
  - methodology 85
  - nociception 94
  - pharmacology 86
  - splice variants 85
  - thalamic dysrhythmias 94
- T-type channels 403
- type-1 diabetes mellitus (T1DM) 215, 237

- GAD65 249
  - insulin 249
  - pathogenesis 249
  - tyrosine kinase 235
- u**
- U-92032 91 ff.
  - UCL-1606 324
  - UCL-1608 324
  - UCL-1684 328
  - UK-78282
    - Hill coefficient 226
    - pharmacological properties 225
    - selectivity 226
  - UK78282 235
    - selectivity 220
    - structure 223
  - urinary incontinence 316
  - use dependence 28, 45
    - inhibition 20
- v**
- V = IR 53
  - $V_{0.5, \text{inact}}$  47
  - valproic acid 87 ff.
  - vascular smooth muscle 55
  - ventricular arrhythmia 339
  - verapamil 90, 278
    - stereoselectivity 105
    - structure 223
  - veratridine 55
  - VGCC modulation 72
  - vinpocetine 174
    - structure 175
  - vitamin D 115
  - volatile anaesthetics 139
  - volsurf 431
  - voltage-dependent
    - block 27, 54
    - inhibition 20
  - voltage-gated calcium channels (VGCC)
    - high voltage activated (HVA) 84
    - low voltage activated (LVA) 84
    - subunit 85
  - voltage-gated  $K^+$  channels 194, 199 ff.
  - voltage-gated sodium channels 151, 393
    - action potential generation 151
    - blockers 168
    - drugs 168
    - impulse propagation 151
    - membrane proteins 151
  - voltage-sensing
    - S4 segments 14
    - dyes 43
- w**
- waggler 77
  - WAY-133537 344
  - WIN 17317-3 319
  - WIN-17317-3 224
    - pharmacological properties 225
    - structure 223
- x**
- XE-991 358 ff., 359
  - xenopus oocytes 39, 50
- y**
- Y5-receptor antagonist 437
- z**
- ZD0947 343
  - ZD6169 343 f.
  - ZM244085 344 f., 347
  - $Zn^{2+}$  86
  - zonisamide 87 ff.

